USA

Tauklarify’s approval comes as the Alzheimer’s diagnostics field increasingly explores less invasive approaches, particularly blood-based tests for phosphorylated tau (pTau).

Lyme disease is transmitted primarily through the bites of infected ticks.

OmniAb was spun out of Ligand Pharmaceuticals in 2022 and has since built a broad network of pharmaceutical partnerships.

The agreement gives Zealand $50 million upfront, with another $50 million payable one year later.

The sale transfers a business that develops and supplies microbiology products used across clinical diagnostics, pharmaceutical manufacturing and food safety testing.

The FDA approval was supported by findings from the Phase 3a ONWARDS clinical program, which evaluated once-weekly Awiqli® in adults with type 2 diabetes.

The transaction will be completed through a share purchase agreement with SEVER Life Sciences, under which Alfasigma will acquire 100% of Nordic Group and its subsidiaries.

The procedures represent the first clinical use of the Aliya EX System since it received U.S. Food and Drug Administration (FDA) 510(k) clearance in May 2026.

The investment forms part of BMS’ broader US$ 40 billion commitment to strengthening its US operations, including its manufacturing and research and development (R&D) capabilities.

As part of the transaction, Actio Biosciences will establish a new privately held company dedicated to developing treatments for genetic rare neurological diseases.